Colgate-Palmolive Company (NYSE: CL) is a Consumer Defensive company in the Household & Personal Products industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 34.93 | EPS (ttm) | 2.52 | Insider Own | 0.18% | Shs Outstand | 800.19M | Perf Week | -1.79% |
| Market Cap | 70.44B | Forward P/E | 21.43 | EPS next Y | 4.11 | Insider Trans | -24.50% | Shs Float | 747.88M | Perf Month | -5.50% |
| Enterprise Value | 76.93B | PEG | 6.36 | EPS next Q | 0.92 | Inst Own | 73.34% | Short Float | 2.35% | Perf Quarter | 0.26% |
| Income | 2.04B | P/S | 3.35 | EPS this Y | 53.46% | Inst Trans | 0.00% | Short Ratio | 3.52 | Perf Half Y | -4.82% |
| Sales | 21.05B | P/B | 124.46 | EPS next Y | 6.24% | ROA | 12.13% | Short Interest | 17.56M | Perf YTD | 11.40% |
| Book/sh | 0.71 | P/C | 51.42 | EPS next 5Y | 5.49% | ROE | 631.14% | 52W High | 99.33 -11.38% | Perf Year | 4.56% |
| Cash/sh | 1.71 | P/FCF | 18.41 | EPS past 3/5Y | 7.28% -3.48% | ROIC | 29.91% | 52W Low | 74.55 18.08% | Perf 3Y | 20.14% |
| Dividend Est. | 2.12 (2.41%) | EV/EBITDA | 20.04 | Sales past 3/5Y | 4.29% 4.35% | Gross Margin | 60.42% | Volatility | 1.55% 1.61% | Perf 5Y | 12.93% |
| Dividend TTM | 2.10 (2.39%) | EV/Sales | 3.66 | EPS Y/Y TTM | -28.21% | Oper. Margin | 20.65% | ATR (14) | 1.69 | Perf 10Y | 17.67% |
| Dividend Ex-Date | Jul 20, 2026 | Quick Ratio | 0.67 | Sales Y/Y TTM | 4.70% | Profit Margin | 9.68% | RSI (14) | 37.60 | Recom | 2.64 |
| Dividend Gr. 3/5Y | 3.46% 3.32% | Current Ratio | 1.03 | EPS Q/Q | 7.61% | SMA20 | -2.89% | Beta | 0.32 | Target Price | 97.78 |
| Payout | 89.45% | Debt/Eq | 21.88 | Sales Q/Q | 4.91% | SMA50 | -3.97% | Rel Volume | 1.02 | Prev Close | 88.41 |
| Employees | 33,600 | LT Debt/Eq | 21.88 | Earnings | Oct 30 | SMA200 | 0.25% | Avg Volume | 4.68M | Price | 88.03 |
| IPO Date | May 02, 1973 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.54% 0.06% | Net Debt/EBITDA | 1.69 | Volume | 4,798,264 | Change | -0.43% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-03-26 | Reiterated | Deutsche Bank | Buy | $99 → $101 |
| Aug-03-26 | Reiterated | Morgan Stanley | Overweight | $100 → $104 |
| Aug-03-26 | Reiterated | UBS | Buy | $100 → $109 |
| Aug-03-26 | Reiterated | RBC Capital | Outperform | $102 → $104 |
| Jul-08-26 | Reiterated | Wells Fargo | Equal Weight | $92 → $95 |
| Jun-11-26 | Initiated | Bernstein | Market Perform on valuation | $96 |
| May-04-26 | Reiterated | Deutsche Bank | Buy | $98 → $99 |
| May-04-26 | Reiterated | UBS | Buy | $93 → $100 |
| Apr-21-26 | Reiterated | Redburn Partners | Neutral | $93 → $100 |
| Apr-21-26 | Upgrade | Rothschild& Co | Neutral → Buy |
Operating globally, Colgate-Palmolive Company and its affiliated entities are engaged in the production and distribution of a diverse range of consumer goods. Its operations are structured into two primary divisions: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care division encompasses a broad array of offerings, spanning oral hygiene (e.g., toothpastes, toothbrushes, mouthwashes), personal care (e.g., bar and liquid soaps, shower gels, shampoos, conditioners, deodorants, antiperspirants, skin health items), and home care solutions (e.g., dishwashing detergents, fabric conditioners, household cleaners). These products are distributed through various channels, including traditional and online retailers, wholesalers, and distributors, under well-known brand names such as Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly. Furthermore, this segment supplies specialized pharmaceutical products to dentists and other professionals in oral healthcare. Conversely, the Pet Nutrition segment focuses on providing specialized pet food. This includes everyday nutritional options marketed under the Hill's Science Diet brand, as well as therapeutic diets designed to assist in managing various health conditions in dogs and cats, sold under the Hill's Prescription Diet brand. Distribution for these pet nutrition items occurs via pet supply stores, veterinary clinics, and online retail platforms. Established in 1806, Colgate-Palmolive Company maintains its corporate headquarters in New York, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 21,046 | 20,382 | 20,101 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 8,329 | 8,131 | 7,995 | — | — | — | — | — | — | |
| Gross Profit | 12,717 | 12,251 | 12,106 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 8,261 | 7,903 | 7,810 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 355 | — | — | — | — | — | — | |
| Other Operating Expense | 116 | 0 | -442 | — | — | — | — | — | — | |
| Operating Income | 4,346 | 4,348 | 4,383 | — | — | — | — | — | — | |
| Interest Expense | 255 | 267 | 292 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1,150 | -1,022 | -135 | — | — | — | — | — | — | |
| Net Income Before Taxes | 2,941 | 3,059 | 3,956 | — | — | — | — | — | — | |
| Income Taxes | 780 | 798 | 907 | — | — | — | — | — | — | |
| Consolidated Net Income | 2,037 | 2,132 | 2,889 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 2,161 | 2,261 | 3,049 | — | — | — | — | — | — | |
| Net Income | 2,037 | 2,132 | 2,889 | — | — | — | — | — | — | |
| EPS (Recurring) | 2.54 | 2.64 | 3.53 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.54 | 2.64 | 3.53 | — | — | — | — | — | — | |
| EPS (Diluted) | 2.52 | 2.63 | 3.51 | — | — | — | — | — | — | |
| EBITDA | 3,838 | 3,956 | 4,853 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 34.93 | 30.05 | 25.90 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.33 | 3.14 | 3.70 | — | — | — | — | — | — | |
| Gross Margin | 60.42 | 60.11 | 60.23 | — | — | — | — | — | — | |
| Operating Margin | 20.65 | 21.33 | 21.80 | — | — | — | — | — | — | |
| Net Margin | 9.68 | 10.46 | 14.37 | — | — | — | — | — | — | |
| Shares Outstanding | 797 | 809 | 818 | — | — | — | — | — | — | |
| Market Capitalization | 70,160 | 63,927 | 74,364 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Tsourapas Panagiotis | COO, CD, EMEA, APac, Skin | Aug 24 '26 | Sale | 92.05 | 10,000 | 920,477 | 64,901 | Aug 26 |
| CAHILL JOHN T | Director | Aug 06 '26 | Sale | 93.37 | 4,170 | 389,358 | 28,373 | Aug 07 |
| CAHILL JOHN T | Director | Aug 06 '26 | Option Exercise | 71.56 | 4,170 | 298,405 | 32,543 | Aug 07 |
| Wallace Noel R. | Chairman, President & CEO | Aug 05 '26 | Option Exercise | 72.29 | 161,021 | 11,640,208 | 523,252 | Aug 06 |
| Wallace Noel R. | Chairman, President & CEO | Aug 05 '26 | Sale | 92.52 | 161,021 | 14,897,904 | 362,231 | Aug 06 |
| Wallace Noel R. | Chairman, President & CEO | Aug 04 '26 | Sale | 91.92 | 161,021 | 14,800,712 | 362,231 | Aug 06 |
| Wallace Noel R. | Chairman, President & CEO | Aug 04 '26 | Option Exercise | 72.29 | 161,021 | 11,640,208 | 161,021 | Aug 06 |
| Malcolm Gregory | EVP and Controller | May 15 '26 | Sale | 88.44 | 2,300 | 203,412 | 13,598 | May 18 |
| Massey Sally | Chief People Officer | May 07 '26 | Sale | 87.41 | 8,599 | 751,633 | 13,785 | May 11 |
| Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | Feb 12 '26 | Option Exercise | 76.41 | 15,000 | 1,146,150 | 25,415 | Feb 13 |
| Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | Feb 12 '26 | Sale | 97.81 | 15,000 | 1,467,111 | 10,415 | Feb 13 |
| Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | Feb 11 '26 | Option Exercise | 76.41 | 35,000 | 2,674,350 | 45,415 | Feb 13 |
| Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | Feb 11 '26 | Sale | 94.61 | 35,000 | 3,311,326 | 10,415 | Feb 13 |
| Hazlin John | Chief Growth Officer | Feb 10 '26 | Option Exercise | 76.41 | 20,989 | 1,603,769 | 38,634 | Feb 12 |
| Hazlin John | Chief Growth Officer | Feb 10 '26 | Sale | 94.25 | 20,989 | 1,978,211 | 17,645 | Feb 12 |